RT Journal Article
SR Electronic
T1 Differential Involvement of the Locus Coeruleus in Early- and Late-Onset Alzheimer’s Disease: A Potential Mechanism of Clinical Differences?
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.11.01.20224139
DO 10.1101/2020.11.01.20224139
A1 Bolton, Corey J.
A1 Tam, Joyce W.
YR 2020
UL http://medrxiv.org/content/early/2020/11/04/2020.11.01.20224139.abstract
AB Early-onset Alzheimer’s disease (EOAD) has been associated with an increased likelihood of atypical clinical manifestations such as attentional impairment, yet the cause of this heterogeneity remains unclear. The locus coeruleus (LC) is implicated early in Alzheimer’s disease pathology and is associated with attentional functioning. This study investigated post-mortem atrophy of the LC in EOAD and late-onset Alzheimer’s disease (LOAD) in a large, well-characterized sample. Results show nearly four times greater likelihood of higher LC atrophy in EOAD as compared to LOAD after controlling for other measures of pathological progression (p < .005). Follow-up analyses within the EOAD group revealed that compared to those who displayed mild or no LC atrophy at autopsy, those with moderate-severe atrophy of the LC displayed significantly worse performance on various baseline measures of attentional functioning (p < .05), despite similar overall cognition (p = .25). These findings suggest the LC is an important potential driver of clinical and pathological heterogeneity in EOAD.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo external funding was received in support of this project.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:As determined by the University of Washington Human Subjects Division, the NACC database itself is exempt from IRB review and approval because it does not involve human subjects, as defined by federal and state regulations. However, all contributing ADCs are required to obtain informed consent from their participants and maintain their own separate IRB review and approval from their institution prior to submitting data to NACC. All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are publicly available through the National Alzheimer's Coordinating Center. https://www.alz.washington.edu